TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04124705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Administered orally once a day; the daily dose could range from 25- 200 µg.
Study: NCT00832429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Undergo lymph node mapping
Study: NCT03846466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/S
Description: IV / Single administration
Study: NCT00535626

Intervention type: DEVICE
Group type: OTHER
Intervention: Trident® Tritanium™ Acetabular Shell
Description: Trident® Tritanium™ Acetabular Shell
Study: NCT03846466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/S
Description: IV / Single administration
Study: NCT00832429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo SLN biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sulfur Colloid
Description: Given ID
Study: NCT02877303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, and PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04115098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT03846466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/M
Description: IV / Multiple administration
Study: NCT04115098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT02961998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Each group will receive sorafenib as basic treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Each group will receive sorafenib as basic treatment.
Study: NCT04272892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy for insomnia
Description: 6 weeks of cognitive behavioural therapy for insomnia (Sleepio) delivered online

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene information
Description: A leaflet detailing advice to improve sleep through changes in sleep hygiene
Study: NCT03846466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/M
Description: IV / Multiple administration
Study: NCT01732757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcaftadine 0.25%
Description: One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine 0.2%
Description: One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
Study: NCT03846466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC/S
Description: SC / Single administration
Study: NCT03010787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single and multiple dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V565
Description: Open-label single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V565
Description: Open-label single ascending dose
Study: NCT06358456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tear
Description: Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tear
Description: Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).
Study: NCT01670552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimesulide + Pantoprazole
Description: 1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen + Esomeprazole
Description: 1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
Study: NCT01732757

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Description: One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
Study: NCT04115098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT03522909

Intervention type: OTHER
Intervention: Seen in clinic
Description: We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~1. Primary outcome variable.~   - Hospital length of stay~2. Secondary outcome variables.~   * Number of admissions from outside hospitals~  * Adverse outcomes~  * Intensive Care Unit admissions~  * Opioid use~  * NICU admissions~  * Patient satisfaction~  * Cost of inpatient admission~  * Cost of outpatient care~  * Hospital readmissions rate
Study: NCT00873496

Intervention type: DRUG
Intervention: Hydroxychloroquine
Study: NCT02675699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimisation + HENRY
Description: HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HENRY as standard
Description: Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
Study: NCT00190385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic screening
Description: Ultrasonographic screening
Study: NCT04123743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trigonella foenum-graceum extract topical cream
Description: Topical cream containing Trigonella foenum-graceum extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Facial Wash
Description: Wardah brand facial wash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Wash
Description: Wardah brand facial wash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen Cream
Description: Parasol sunscreen cream SPF 33

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Cream
Description: Parasol sunscreen cream SPF 33

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical cream
Study: NCT00240331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg Rosuvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01624818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac habilitation program
Description: physical activity three weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac habilitation program
Description: physical activity three weeks
Study: NCT02873598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX or gemcitabine/abraxane
Description: Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX or gemcitabine/abraxane
Description: Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX or gemcitabine/abraxane
Description: Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
Study: NCT03252067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin eyedrop
Description: Tear samples will be collected using the strips.
Study: NCT02873598

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
Study: NCT03914456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation treatment
Study: NCT04823078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity base therapy
Description: activity based therapy~Weight bearing activities of daily living like vertical lifting, bilateral body weight shifting, lifting and shifting, forward reaching and sideways reaching.

Intervention type: OTHER
Group type: OTHER
Intervention: Strength training
Description: Strengthening exercises of upper limb involved muscles (elbow extensors, shoulder adductors, abductors, wrist extensors, shoulder protractors and retractors
Study: NCT04115098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT01973699

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: visualization in shoulder arthroscopy
Description: Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
Study: NCT06358456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tear
Description: Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).
Study: NCT01973699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visualization in shoulder arthroscopy
Description: Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
Study: NCT04917588

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Saypha® FILLER Lidocaine (HQ)
Description: Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
Study: NCT00544635

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: no intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light
Description: scars will be treated with light
Study: NCT04917588

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Saypha® FILLER Lidocaine (C1)
Description: Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
Study: NCT03025295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is common used to improve the prognosis and life quality of patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: It is safe Placebo.
Study: NCT02144142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moisturizer with each subject's own antimicrobial bacteria
Study: NCT00579605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
Study: NCT04648943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ex-Press mini shunt insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Study: NCT05723120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment Respiratory and Neuromuscular
Description: Comparative Score

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment Respiratory and Neuromuscular
Description: Comparative Score
Study: NCT01830621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BBI608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Study: NCT00187655

Intervention type: DRUG
Group type: OTHER
Intervention: Cefotaxime
Description: Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
Study: NCT04282551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention with oligosaccharides
Description: intervention with oligosaccharide 1 or 2, or placebo, given once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention with oligosaccharides
Description: intervention with oligosaccharide 1 or 2, or placebo, given once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dietary intervention with oligosaccharides
Description: intervention with oligosaccharide 1 or 2, or placebo, given once a day
Study: NCT03383406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy
Description: Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion.
Study: NCT00727246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP-Choline
Description: 1000 mg CDP-Choline 2 x per day for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo for 6 weeks
Study: NCT01288820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/piperaquine + primaquine
Description: Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-amodiaquine + primaquine
Description: Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
Study: NCT06358456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No artificial tears
Description: Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention
Study: NCT04652245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3
Description: Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5
Description: Single dose, one spray in each nostril of Placebo nasal spray at Visit 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5
Description: Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3
Description: Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
Study: NCT04115098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT01786707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stem cells
Description: Pancreatic artery infusion of Autologous Stem cells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy